AHCO Stock Recent News

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that AdaptHealth granted restricted stock units covering 553,251 shares of the Company's common stock at target performance levels (the “Inducement RSUs”) to Suzanne Foster, AdaptHealth's newly appointed Chief Executive Offi.

Finding investing opportunities in the market might be challenging. Nevertheless, three equities stick out due to their ability to yield large profits during volatility.

AdaptHealth came public in 2019 through a SPAC merger and has been in the penalty box as other SPACS crashed the past 2 years. Yet earnings are growing rapidly and revenues are also steadily growing. Earnings strength has been masked by non-recurring items related to mergers and goodwill write-offs and management not showing an adjusted EPS.

AdaptHealth Corp. (AHCO) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ago.

Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its first quarter 2024 financial results before the opening of the financial markets on Tuesday, May 7, 2024. Management will host a teleconference at 8:30 a.m. ET to discuss the results and business activities with analysts an.

One of the pharmaceutical giant's hotter medications tested well for a new indication. It has already attracted much attention for the molecule being studied, as it's used in two FDA-approved treatments already.

Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.